Delcath Systems' Targeted Drug Delivery System for Liver Cancer Treatment to Be Featured on FOX Business News

NEW YORK, NY--(Marketwire - July 15, 2008) - Delcath Systems, Inc. (NASDAQ: DCTH) today announced that CEO Richard L. Taney will appear on FOX Business Network (FBN) to discuss the Company's proprietary Percutaneous Hepatic Perfusion (PHP) System, which is designed to deliver targeted high doses of therapeutic and chemotherapeutic agents. The PHP System is currently being tested in Phase III and II clinical trials for the treatment of hepatocellular carcinoma and metastatic tumors in the liver. Also appearing on this segment will be Dr. James Pingpank of the National Cancer Institute in Bethesda, Maryland. Dr. Pingpank is the Principal Investigator for the Company's ongoing pivotal Phase III trial of metastatic melanoma in the liver. Mr. Taney will discuss the health industry's efforts towards treating cancer on a regionalized basis and provide an update on current approaches to the treatment of liver cancer, including Delcath's PHP System. Mr. Taney will be featured on the "Money for Breakfast" segment on Wednesday, July 16, 2008 to be broadcast at 7:30 AM/ET.

In making this announcement, Mr. Taney commented, "The appearance on FOX Business News is an important step in our ongoing effort to increase public awareness of the Company's targeted drug delivery system for the treatment of liver cancers. We are pleased to have the opportunity to present our technology and the promise that it holds for patients suffering from this terrible disease."

FOX Business Network (FBN) is a financial news channel delivering real-time information across all platforms that impact both Main Street and Wall Street. FBN is headquartered in New York, the business capital of the world. Launched in October 2007, the Network is available in more than 35 million homes in major markets across the United States. Owned by News Corp., the Network has bureaus in Chicago, Los Angeles, Silicon Valley, Washington, DC and London. (www.foxbusiness.com).

About Delcath Systems, Inc.

Delcath Systems is a technology-based therapeutic company specializing in cancer treatment. The Company is working to complete its first Phase III clinical trial for its Percutaneous Hepatic Perfusion System ("PHP") for the isolated delivery of high doses of therapeutic and chemotherapeutic agents. The PHP System is currently being tested in Phase III and Phase II clinical trials for the treatment of hepatocellular carcinoma and metastatic tumors in the liver, including melanomas, neuroendocrine tumors and adenocarcinomas. The Company's intellectual property portfolio currently consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

Contact Information: Delcath Systems, Inc. Contact: Mr. Richard Taney President & Chief Executive Officer T: (212) 489-2100 E: Investor Relations Contact: Mr. Richard Cooper Chairman Mr. Cass Almendral Vice President Strategic Growth International, Inc. T: 212-838-1444 E: